Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Fears over flu jab adverse reactions in children

Till now more than 250 under five kids have developed some or other adverse reaction to seasonal flu jabs. There has been a mad rush at the adverse events hotline with many parents and healthcare staff panicking as more reports are streaming in. Initially there was a spike in cases in Western Australia but now more cases are being reported from Queensland and South Australia. The affected children developed fever, vomiting and seizures. Even New Zealand has reported three cases of febrile convulsions.

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Toddler dies after seasonal flu shot – health authorities on alert

Last Friday, Australia's Chief Medical Officer Professor Jim Bishop had announced his decision to suspend free seasonal flu vaccinations after more than 20 under-five kids mainly in Western Australia developed reactions to the shots. They developed fever, vomiting and convulsions. One of the children was reported to be severely ill.

25 Apr 2010

Overweight adolescent children tend to follow weight-control strategies of their parents: Study

When parents maintain a healthy body image and weight-control strategies, overweight adolescent children tend to follow their example, a new study reveals.

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Drinking lemonade prevents kidney stone formation

We've all heard the expression, "when life gives you lemons, make lemonade." Passing a kidney stone would qualify for one of life's "lemons," but did you know that drinking lemonade has been shown to prevent them?

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

The seasonal flu vaccine has caused serious side effects in dozens of children in Western Australia (WA) and following this the Health Department has suspended further free flu vaccinations for under-fives. There has been as rise in admissions to Princess Margaret Hospital. The side effects to the flu vaccine include fever, vomiting and often seizures related to high fever, also known as febrile convulsions. One of the children is seriously ill at present.

22 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

BDSI Sciences to purchase $10M of securities in registered direct offering

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

FDA approves Lannett's ANDA for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.

20 Apr 2010

Vomiting News and Research

Further Reading

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Fears over flu jab adverse reactions in children

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Toddler dies after seasonal flu shot – health authorities on alert

Overweight adolescent children tend to follow weight-control strategies of their parents: Study

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Drinking lemonade prevents kidney stone formation

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Seasonal flu vaccine causing serious side effects in under-fives: Ban on flu vaccination program

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

BDSI Sciences to purchase $10M of securities in registered direct offering

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

FDA approves Lannett's ANDA for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News